The FDA has fired off warning letters to Nephron Pharmaceuticals and obesity med Contrave’s owner, Nalpropion Pharmaceuticals.

The Office of Prescription Drug Promotions (OPDP) reprimanded Nephron for emails promoting budesonide, while Nalpropion’s warning centered on a Google link promoting Contrave. Warning letters are OPDP’s strongest rebuke for improper pharma promotions.